MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Tanshinone I

CAS No. : 568-73-0

MCE 站：Tanshinone I

产品活性：Tanshinone I 是一种IIA型人重组 sPLA₂ 和兔重组 cPLA₂ 抑制剂，IC₅₀ 分别为 11 μM 和 82 μM。

研究领域：Metabolic Enzyme/Protease

作用靶点：Phospholipase

In Vitro: Tanshinone I inhibits PGE₂ formation from LPS-induced RAW macrophages (IC₅₀=38 μM). When Tanshinone I is added simultaneously with LPS, this compound clearly inhibits PGE2 production (IC₅₀=38 μM) at 10-100 μM. Tanshinone I also reduces PGE2 production (IC₅₀=46 μM) when added after COX-2 is fully induced. The fact that Tanshinone I inhibits PGE2 production by pre-induced COX-2 strongly suggests that this compound may directly inhibit COX-2 activity and/or affect PLA₂ activity. When Tanshinone I is incubated with two different forms of phospholipase A₂ (PLA₂), it clearly inhibits sPLA₂ (IC₅₀=11 μM) in a concentration-dependent manner. Although being less potent, Tanshinone I also inhibits cPLA₂ (IC₅₀=82 μM).

In Vivo: Tanshinone I shows antiinflammatory activity in rat carrageenan-induced paw oedema and adjuvant-induced arthritis. In order to establish the anti-inflammatory activity of Tanshinone I, the classical animal models of acute and chronic inflammation [rat carrageenan (CGN)-induced paw oedema and rat adjuvant-induced arthritis (AIA)] are employed. When Tanshinone I is orally administered, it shows significant anti-inflammatory activity against CGN-induced paw oedema (47% inhibition at 160 mg/kg), while the IC₅₀ of indomethacin is 7.1 mg/kg. In AIA, Tanshinone I gives 27% inhibition of secondary inflammation at 18 day with an oral dose of 50 mg/kg/day, whereas prednisolone (5 mg/kg/day) shows potent inhibition (65%).

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  NMPA-Approved Drug Library  |  Terpenoids Library  |  Traditional Chinese Medicine Monomer Library  |  FDA Approved & Pharmacopeial Drug Library  |  GW4869  |  Neomycin sulfate  |  U-73122  |  D609  |  Omeprazole  |  N-(p-amylcinnamoyl) Anthranilic Acid  |  Varespladib  |  Lansoprazole  |  Tris(2,4-di-tert-butylphenyl)phosphate  |  3-Nitrocoumarin  |  MAFP  |  ML349  |  1-Naphthaleneacetic acid  |  Cambinol  |  CAY10650  |  Melittin  |  FIPI  |  U-73343  |  Bromoenol lactone  |  Compound 48/80 trihydrochloride  |  LCL521  |  m-3M3FBS  |  1-Linoleoyl Glycerol  |  Lp-PLA2-IN-1  |  RHC 80267  |  Halopemide  |  SPK-601

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。